Bicara Therapeutics Inc. 8-K

What Happened
Bicara Therapeutics, Inc. (BCAX) announced its financial results and business highlights for the fiscal year and quarter ended December 31, 2025 via a press release dated March 30, 2026. The company furnished the full press release as Exhibit 99.1 to its Form 8‑K (filed March 30, 2026). The Form 8‑K was signed by Chief Executive Officer Claire Mazumdar.

Key Details

• Filing: Current Report on Form 8‑K filed March 30, 2026 covering Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).
• Period covered: Fiscal year and quarter ended December 31, 2025.
• Exhibit: Press release dated March 30, 2026 furnished as Exhibit 99.1; Inline XBRL cover page included as Exhibit 104.
• Signed by: Claire Mazumdar, Chief Executive Officer, on behalf of the company.

Why It Matters
The Form 8‑K notifies investors that Bicara has publicly released its latest earnings and operational highlights for FY/quarter-end Dec 31, 2025. Retail investors should read the furnished press release (Exhibit 99.1) and any accompanying SEC filings for the specific financial metrics—such as revenue, net loss/profit, cash position, and management commentary—as those figures are what will drive market reaction and inform investment decisions.